A Single Dose-escalation and Dose-expansion Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Refractory or Relapsed B Cell Lymphoma.
Latest Information Update: 23 Mar 2023
At a glance
- Drugs Cyclophosphamide (Primary) ; Etoposide (Primary) ; Fludarabine (Primary) ; ThisCART 19 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 23 Mar 2023 New trial record